Buds & Duds: Cannabis stocks higher on Thursday as troubled retailer MedMen reveals new round of layoffs

1933 Industries got a lift on a second licensing agreement in the US

cannabis stocks arrow
Also moving on Thursday: Valens GroWorks, Emerald Health Therapeutics and Aleafia Health

Cannabis indices were up on Thursday as a major multistate operator announced a further round of layoffs in North America.

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, was 1.3% higher to 112.8 points. Elsewhere, the Horizons Marijuana Life Sciences Index ETF rose 0.4% at C$9.06, while the OTCQX Cannabis index gained 0.6% to 428.6 points.


After a corporate update released on Wednesday evening that saw the firm laying off another 20% of its employees, pot retailer MedMen Enterprises Inc (CSE:MMEN) skyrocketed 12.3% in Canada and 9.5% over the counter in the US.

The California-based firm also announced some new financing that will result in US$37 million in new proceeds, according to a release.

Shares of MedMen traded at C$0.63 and US$0.48 on Thursday morning.

1933 Industries Inc (CSE:TGIF) (OTCMKTS:TGIFF) saw its shares up on Thursday’s news that it has signed a second licensing agreement with OG DNA Genetics, a globally recognized leading cannabis brand.

The agreement will grant 1933 Industries the license to the DNA brand for the production and sale of hemp-derived CBD products – signaling DNA’s first entry into the cannabidiol market – while DNA will leverage 1933’s vast distribution network of over 800 retail outlets throughout the US.

Shares of 1933 were up 2.6% in Canada at C$0.20 and were trading at US$0.15 over the counter.

Extraction firm Valens Groworks Corp (CVE:VGW) (OTCMKTS:VGWCF) said Thursday that it has stuck an amended manufacturing and sales licence agreement with SōRSE Technology Corporation, which granted it an exclusive licence for Canada, Europe, Australia and Mexico to use the proprietary SōRSE emulsion technology to produce, sell and distribute cannabis-infused products.

Valens nudged 0.7% higher in Canada at C$2.93 and 1% higher over the counter at US$2.23.


Emerald Health Therapeutics Inc (CVE:EMH) (OTCMKTS:EMHTF) was trading 3.6% lower in Canada at C$0.27 and 5.8% lower over the counter on Thursday morning. The Vancouver-based company’s latest financials were disappointing, with the firm posting a C$17.5 million net loss on the back of a nearly C$3 million writedown of assets.

Also lower was Aleafia Health Inc (TSE:ALEF) (OTCMKTS:ALEAF), which announced two days ago that it had partnered with a Toronto-based college to provide cannabis education programming. Shares of Aleafia were down 1.6% in Toronto at C$0.63 but higher on the OTC Pink market at US$0.48.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



District Metals continues to unlock potential with more strong historical...

District Metals (CVE: DMX) CEO Garrett Ainsworth continues to unlock the mysteries of their project called TomTebo. Ainsworth telling Proactive’s Steve Darling they have released more historical results, this time from the Gårdsgruvans zone. Ainsworth said the results are telling them these...

5 hours, 25 minutes ago

3 min read